CD163 and melanoma: Tissue from a patient with Nivolumab-resistant metastatic melanoma showed a remarkable increase in expression of IL-34 compared with primary site melanoma tissues, and this upsurge in expression was demonstrated to be connected with greater frequencies of CD163, an M2 macrophage marker (77).